EUVIMEDEUVIMED entdecken
Open Access

Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia

Zubeyir Hasan Gun, Charles Osamor, Jocelyn Taylor, Xiaobai Li, Vivian Szymczuk, Alison M Boyce iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Zubeyir Hasan Gun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Scoliosis, Fibrous Dysplasia of Bone, Fibrous Dysplasia, Polyostotic, Hypophosphatemia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CLC NIH HHS, Intramural Research Programs, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Fibrous dysplasia (FD) results in fractures, pain, and deformities. Abnormal osteoprogenitor cells overproduce FGF23, leading to hyperphosphaturia in most patients and frank hypophosphatemia in a subset. Studies suggest hypophosphatemia is associated with increased FD-related morbidity. However, the relationship between phosphorus and skeletal complications has not been investigated, and the optimal therapeutic target has not been determined.

Objective

Characterize the impact of serum phosphorus on FD-related morbidity and identify levels associated with increased skeletal complications.

Methods

Natural history study with 240 subjects at a clinical research center who had ≥1 fasting phosphorus level, determined as age- and sex-adjusted Z-scores. Subjects were categorized based on frank hypophosphatemia (Z-score ≤ −2; n = 48); low-normophosphatemia (> −2 to ≤ −1; n = 66); and high-normophosphatemia (> −1 to ≤ 2; n = 125). Main outcomes were fractures, orthopedic surgeries, and scoliosis.

Results

Subjects with frank and low-normophosphatemia had increased fracture and surgery rates vs high-normophosphatemia. The prevalence of moderate to severe scoliosis was similarly higher in the frank and low-normophosphatemia groups. In a subanalysis of patients matched for Skeletal Burden Score ≥35, fracture and surgery rates remained higher in the frank hypophosphatemia group, suggesting association between phosphorus and skeletal complications is not explained by differences in FD burden alone.

Conclusion

Both frank hypophosphatemia and low-normophosphatemia are associated with increased FD-related complications. This supports FGF23-mediated hypophosphatemia as a driver of skeletal morbidity, which may impact a larger proportion of the FD/McCune-Albright syndrome population than previously recognized. These findings enable clinicians to identify at-risk patients and will inform development of prospective studies to determine optimal therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ScoliosisFibrous Dysplasia of BoneFibrous Dysplasia, PolyostoticHypophosphatemiaFractures, BoneHumansPhosphorusProspective StudiesPrevalence

Stichwörter der Autor:innen

McCune-Albright syndromefibroblast growth factor-23fracturesmetabolic bone diseasepediatricsscoliosis

Substanzen

Phosphorus

Autor:innen und Institutionen

  • Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pediatric Endocrinology Inter-Institute Training Program, National Institute of Child Health and Development, National Institutes of Health, Bethesda, MD 20892, USA.
  • Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Alison M Boyce

Förderung

  • CLC NIH HHS
  • Intramural Research Programs
  • NIH
  • NIDCR
  • NICHD
  • Clinical Center

Zitieren

APA

Gun, Z. H., Osamor, C., Taylor, J., Li, X., Szymczuk, V., & Boyce, A. M. (2024). Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad671

Vancouver

Gun ZH, Osamor C, Taylor J, Li X, Szymczuk V, Boyce AM. Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad671

BibTeX
@article{Gun2024,
  author = {Gun, Zubeyir Hasan and Osamor, Charles and Taylor, Jocelyn and Li, Xiaobai and Szymczuk, Vivian and Boyce, Alison M},
  title = {Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad671}
}
Kostenlos starten →